The opposing associations of AGR2 and ESR1 expression with DSS could reflect the role of AGR2 in hormone therapy- resistant ER+ breast cancer: ER+ breast cancers may develop resistance by overexpressing AGR2 [12–14]. The gene discussed is ESR1; the disease is breast carcinoma.